460 related articles for article (PubMed ID: 12820450)
41. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients.
Cahn JY; Bordigoni P; Souillet G; Pico JL; Plouvier E; Reiffers J; Benz-Lemoine E; Bergerat JP; Lutz P; Colombat P
Bone Marrow Transplant; 1991 Jan; 7(1):1-4. PubMed ID: 2043871
[TBL] [Abstract][Full Text] [Related]
42. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL
Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320
[TBL] [Abstract][Full Text] [Related]
43. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum W; Bolwell BJ; Phillips G; Farag SS; Lin TS; Avalos BR; Penza SL; Marcucci G; Byrd JC; Kalaycio ME; Sobecks RM; Pohlman B; Brown S; Elder PJ; Copelan EA
Biol Blood Marrow Transplant; 2006 Jan; 12(1):61-7. PubMed ID: 16399569
[TBL] [Abstract][Full Text] [Related]
44. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
45. Poor prognosis acute myeloid leukaemia treated by matched unrelated donor marrow transplant without preceding total body irradiation.
Kanfer EJ; Macdonald I; Hall G; Ward H; Smith J; Evans M; Taylor J; Camba L; Glaser MG; Samson DM
Bone Marrow Transplant; 1992 Jan; 9(1):67-9. PubMed ID: 1543953
[TBL] [Abstract][Full Text] [Related]
46. High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia.
Sato N; Furukawa T; Kuroha T; Hashimoto S; Masuko M; Takahashi H; Yano T; Abe T; Fuse I; Koike T; Kishi K; Aizawa Y
Bone Marrow Transplant; 2004 Aug; 34(4):299-303. PubMed ID: 15195078
[TBL] [Abstract][Full Text] [Related]
47. High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia.
Martino R; Badell I; Brunet S; Sureda A; Torras A; Cubells J; Domingo-Albós A
Bone Marrow Transplant; 1995 Aug; 16(2):209-12. PubMed ID: 7581138
[TBL] [Abstract][Full Text] [Related]
48. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.
Helenglass G; Powles RL; McElwain TJ; Lakhani A; Milan S; Gore M; Nandi A; Zuiable A; Perren T; Forgeson G
Bone Marrow Transplant; 1988 Jan; 3(1):21-9. PubMed ID: 3048467
[TBL] [Abstract][Full Text] [Related]
49. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
[TBL] [Abstract][Full Text] [Related]
50. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
51. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation.
Le Blanc K; Ringdén O; Remberger M
Haematologica; 2003 Sep; 88(9):1044-52. PubMed ID: 12969813
[TBL] [Abstract][Full Text] [Related]
52. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sharathkumar A; Saunders EF; Dror Y; Grant R; Greenberg M; Weitzman S; Chan H; Calderwood S; Freedman MH; Doyle J
Bone Marrow Transplant; 2004 Jan; 33(1):39-45. PubMed ID: 14566329
[TBL] [Abstract][Full Text] [Related]
54. Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Dai QY; Souillet G; Bertrand Y; Galambrun C; Bleyzac N; Manel AM; Bruno B; Souillet AL; Homole E; Pages MP; Berlier P; David M; Berthier JC; Massenavette B; Contamin B; Philippe N
Bone Marrow Transplant; 2004 Oct; 34(8):667-73. PubMed ID: 15354203
[TBL] [Abstract][Full Text] [Related]
55. [Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia].
Matsuyama T; Kato K; Hanada R; Kawa K; Okamura J; Tsuchida M; Kigasawa H; Watanabe A; Hamamoto K; Kudoh T; Sano K; Ohira M;
Rinsho Ketsueki; 2002 Jul; 43(7):527-37. PubMed ID: 12229121
[TBL] [Abstract][Full Text] [Related]
56. Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
Russell S; Vowels M
Transplant Proc; 1992 Feb; 24(1):183. PubMed ID: 1539236
[No Abstract] [Full Text] [Related]
57. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD-BMT).
Corvò R; Lamparelli T; Bruno B; Barra S; Van Lint MT; Vitale V; Bacigalupo A
Bone Marrow Transplant; 2002 Dec; 30(11):717-23. PubMed ID: 12439693
[TBL] [Abstract][Full Text] [Related]
58. [Bone marrow transplantation in the treatment of acute leukemias].
Moiseev SI; Ganapiev AA; Abdulkadyrov KM
Ter Arkh; 1996; 68(12):8-10. PubMed ID: 9054052
[TBL] [Abstract][Full Text] [Related]
59. Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
Ayash LJ; Ratanatharathorn V; Braun T; Silver SM; Reynolds CM; Uberti JP
Am J Hematol; 2007 Jan; 82(1):6-14. PubMed ID: 16986128
[TBL] [Abstract][Full Text] [Related]
60. Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Saarinen UM; Mellander L; Nysom K; Ringden O; Schroeder H; Glomstein A; Gustafsson G
Bone Marrow Transplant; 1996 Mar; 17(3):357-63. PubMed ID: 8704687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
